127 related articles for article (PubMed ID: 12205498)
1. Just mad about mAbs.
Jacobs T
Nat Biotechnol; 2002 Sep; 20(9):869. PubMed ID: 12205498
[No Abstract] [Full Text] [Related]
2. Tysabri back on market.
Sheridan C
Nat Biotechnol; 2006 Aug; 24(8):874. PubMed ID: 16900111
[No Abstract] [Full Text] [Related]
3. Anti-inflammatory inflames Centocor's profits.
Glaser V
Nat Biotechnol; 1998 Oct; 16(10):900. PubMed ID: 9788334
[No Abstract] [Full Text] [Related]
4. Next-generation monoclonals less profitable than trailblazers?
Mitchell P
Nat Biotechnol; 2005 Aug; 23(8):906. PubMed ID: 16082347
[No Abstract] [Full Text] [Related]
5. Why these biotechs are as hot as net stocks. Wall Street's betting big on a genetic technology that burned it badly before. Monoclonal antibodies still don't cure cancer--but this time they may actually pay off.
McLean B
Fortune; 2000 Jan; 141(1):132-4, 135. PubMed ID: 10788044
[No Abstract] [Full Text] [Related]
6. Genentech relaunched with independence intact.
Glaser V
Nat Biotechnol; 1999 Jul; 17(7):634. PubMed ID: 10409348
[No Abstract] [Full Text] [Related]
7. The drug that could have been.
Schultz S
US News World Rep; 2002 Aug; 133(7):18, 20-3. PubMed ID: 12195678
[No Abstract] [Full Text] [Related]
8. Can next-generation antibodies offset biosimilar competition?
Mullard A
Nat Rev Drug Discov; 2012 Jun; 11(6):426-8. PubMed ID: 22653202
[No Abstract] [Full Text] [Related]
9. Can 'double blockbuster' strengthen Amgen's backbone?
Sheridan C
Nat Biotechnol; 2008 Apr; 26(4):361-3. PubMed ID: 18391999
[No Abstract] [Full Text] [Related]
10. Spinning the wheel on ImClone.
Varchaver N
Fortune; 2003 Apr; 147(8):123-5. PubMed ID: 12728651
[No Abstract] [Full Text] [Related]
11. Are mAbs different?: a comment on Cohen and Wilson.
Neumann PJ
MAbs; 2009; 1(1):29-30. PubMed ID: 20046571
[No Abstract] [Full Text] [Related]
12. Tysabri's troubles return.
Hoag H
Nat Biotechnol; 2008 Oct; 26(10):1061. PubMed ID: 18846062
[No Abstract] [Full Text] [Related]
13. IL-1 trap go-ahead.
Ratner M
Nat Biotechnol; 2008 May; 26(5):485. PubMed ID: 18464767
[No Abstract] [Full Text] [Related]
14. AHP's awful losing streak.
Whitford D
Fortune; 1999 Nov; 140(10):52, 56. PubMed ID: 10662389
[No Abstract] [Full Text] [Related]
15. Antibiotics--an investment worth making?
Christoffersen RE
Nat Biotechnol; 2006 Dec; 24(12):1512-4. PubMed ID: 17160052
[TBL] [Abstract][Full Text] [Related]
16. Fast track to MS drug.
Sheridan C
Nat Biotechnol; 2004 Aug; 22(8):939-41. PubMed ID: 15286635
[No Abstract] [Full Text] [Related]
17. Fresh from the biologic pipeline-2009.
Sheridan C
Nat Biotechnol; 2010 Apr; 28(4):307-10. PubMed ID: 20379168
[No Abstract] [Full Text] [Related]
18. A dose of reality for rational therapies.
Nat Biotechnol; 2005 Mar; 23(3):267. PubMed ID: 15765066
[No Abstract] [Full Text] [Related]
19. Monoclonal antibodies market.
Reichert J; Pavolu A
Nat Rev Drug Discov; 2004 May; 3(5):383-4. PubMed ID: 15152631
[No Abstract] [Full Text] [Related]
20. A cancer drug shows promise, at a price that many can't pay.
Berenson A
N Y Times Web; 2006 Feb; ():A1, C2. PubMed ID: 16506302
[No Abstract] [Full Text] [Related]
[Next] [New Search]
